FindTrial
Sign In

Combination of Aprepitant and Transcutaneous Acupoint Electrical Stimulation for the prophylaxis of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a prospective randomized controlled study.

Combination of Aprepitant and Transcutaneous Acupoint Electrical Stimulation for the prophylaxis of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a prospective randomized controlled study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024389
Enrollment
Unknown
Registered
2019-07-09
Start date
2019-08-01
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting after gynecological surgery

Interventions

control group:aprepitant 80 mg
test group:80 mg of aprepitant plus transcutaneous electric stimulation at bilateral Neiguan and Zusanli acupoints

Sponsors

Department of Anesthesiology, Chifeng Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1 ASA grading I to III; 2 Aged 18 to 65 years; 3 BMI 18-30 kg/m2; 4 Selective gynecological laparoscopic surgery under general anesthesia; 5 Voluntary and signed informed consent; 6 Female, history of motion sickness or PONV, and Apfel score greater than or equal to 3.

Exclusion criteria

Exclusion criteria: 1 Preoperative use of antiemetic drugs; 2 Preoperative patients with severe hypertension, heart disease and diabetes mellitus; 3 Preoperative severe liver and kidney dysfunction; 4 those who have received electro-acupuncture stimulation therapy; 5 The contraindication of transcutaneous acupoint electrical stimulation, including skin damage, infection or electrophysiological devices in the needle site implants; 6 Can not cooperate with the research for any reason, such as language comprehension disorder, psychiatric patients, etc.; 7 Perioperative use of anticholinergics; 8 Participated in other clinical trials within 3 months before being selected for the study.

Design outcomes

Primary

MeasureTime frame
Incidence of nausea within 24 hours after operation;—

Secondary

MeasureTime frame
Complete remission (CR) and remedial antiemetic therapy within 0-6 hours, 6-24 hours and 0-24 hours after operation;Incidence of postoperative nausea and vomiting within 24 hours after operation;VAS score of nausea at 2, 6 and 24 hours after operation;the numbers of patients with PCA pump stopping and remedial analgesia for nausea and vomiting within 24 hours after operation;—

Countries

China

Contacts

Public ContactQi Zhou

Department of Anesthesiology, Chifeng Municipal Hospital

18842513341@163.com+86 13848877505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026